Immunological Effects Of Minimally Invasive Therapies In Patients With Hepatocellular Carcinoma
- Conditions
- C22.0Liver cell carcinoma
- Registration Number
- DRKS00026994
- Lead Sponsor
- Charité Campus Virchow-Klinikum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 126
Inclusion Criteria
non-resectable HCC with tumor board reviewed recommendation for minimally-invasive therapies including TACE and HDRBT
Exclusion Criteria
other malignancies of the liver excluding HCC
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Treatment response - measured by standardized, image morphological criteria such as (m)RECIST at defined time points (after 8-10 weeks, after 5 months, and subsequently every 3-6 months post-intervention).
- Secondary Outcome Measures
Name Time Method Overall survival, Progression-free survival - measured by reporting data from the hospital's own documentation system as well as national cancer registries and, if applicable, registration offices.